Psilera will participate in two separate research studies with NIDA to combat addiction using a novel DMT intranasal formulation and new psychedelic-inspired compounds TAMPA, Fla., Aug. 26, 2021 /PRNewswire-PRWeb/ — Psilera Inc. (“Psilera”), a Florida-based biotechnology company specializing in the clinical development of psychedelics and analogues, has finalized a Cooperative Research and…


Previous articleMYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering
Next articleScientists Isolate Two New Compounds from Toad Venom